MedPath

Multicenter Study Evaluating the FixNip™ NRI Safety and Performance

Not Applicable
Completed
Conditions
Reconstruction of the Breast Nipple and Areola Complex
Interventions
Device: FixNip™ NRI
Registration Number
NCT04051892
Lead Sponsor
FixNip Ltd
Brief Summary

A prospective, Open Label, Single arm, Multicenter study Evaluating the FixNip™ NRI Safety and Performance in Female Patients Seeking Reconstructive Surgery of the Nipple.

Detailed Description

This is a Prospective, Open label, Single arm, Multicenter Study enrolling female patients with a history of breast cancer following breast conservation surgery or mastectomy with breast reconstruction, seeking reconstruction of the breast nipple and areola complex.

The study is designed to evaluate the long-term safety and performance of the FixNip NRI in patients undergoing nipple reconstruction procedure.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
10
Inclusion Criteria
  • Women between the ages of 22-70 years.
  • Patients of childbearing potential must agree to use methods of contraception and have negative pregnancy test at screening. Effective methods of contraception must be used throughout the study.
  • History of breast cancer post mastectomy with breast implant or partial mastectomy (lumpectomy) of the central segment of the breast seeking reconstruction of the nipple and/or areola complex.
  • At least 3 months post breast reconstruction surgery.
  • Baker scale grade I or II capsular contracture.
  • No evidence of any systemic or chronic disease that might influence wound healing and infection rate.
  • Event free post breast and/or nipple reconstruction procedure, i.e. no skin infections or related infections that mandated antibiotic therapy, no wound dehiscence or any other related medical complications.
  • Pinch test of intended nipple location on affected breast of at least 15 mm.
  • Patient is willing to postpone tattooing until the end of follow-up period.
  • Patient is willing and able to give their written informed consent.
Exclusion Criteria
  • Active malignant disease.
  • Subject has a chronic disease or any medical status that, according to surgeon discretion, prohibits from inclusion in the study i.e. diabetes.
  • History of tendency to produce hypertrophic scars or keloids.
  • Current use of any medications that can interfere with wound healing, impair the immune system functionality, or impair blood clotting mechanisms.
  • Active infection within the last 30 days.
  • Pregnant or nursing women.
  • Connective tissue disease.
  • 'Lupus disease' defined as Systemic Lupus Erythematous or Discoid Lupus, or scleroderma defined as Progressive Systemic Sclerosis per history.
  • Chronically treated with steroids or steroid therapy in a 3month period before surgery.
  • Demonstrate psychological characteristics, which, in the opinion of the Investigator and/or consulting physician(s) are incompatible with the risks, involved with the surgical procedure, prosthesis and compliance with follow-up recommendations.
  • Past or current capsular contracture defined as Baker III or IV.
  • Participating in any other investigational study for either drug or device which can influence collection of valid data under this study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Implantation of FixNip™ NRIFixNip™ NRIFemale Patients Seeking Reconstructive Surgery of the Nipple
Primary Outcome Measures
NameTimeMethod
Adverse event12 months

Frequency and severity of Adverse Event . All adverse events occurring during the study will be reported

Secondary Outcome Measures
NameTimeMethod
Nipple Projection12 months

Nipple projection in millimeter (mm)

Trial Locations

Locations (1)

Assuta Medical Center

🇮🇱

Tel Aviv, Israel

© Copyright 2025. All Rights Reserved by MedPath